Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/fondaparinux-sodium-0O6JsZhBQs
References (62)
-
J. Lormeau, J. Herault, J. Herbert (1996)
Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin.Thrombosis and haemostasis, 76 1
-
S. Olson, I. Björk, R. Sheffer, P. Craig, J. Shore, J. Choay (1992)
Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement.The Journal of biological chemistry, 267 18
-
M. Hamon, S.K. Mehta, G. Steg (2006)
Major bleeding in patients with acute coronary syndrome undergoing early invasive management can be reduced by fondaparinux, even in the context of trans-radial coronary intervention: insights from OASIS-5 trial [abstract no. 2654]Circulation, 114
-
J.H. Alexander, K.P. Singh (2005)
Inhibition of Factor Xa: a potential target for the development of new anticoagulantsAm J Cardiovasc Drugs, 5
-
K. Fox, S. Goodman, W. Klein, D. Brieger, P. Steg, O. Dabbous, Á. Avezum (2002)
Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE).European heart journal, 23 15
-
S. Jolly, S.R. Mehta, L. Wallentin (2007)
The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial [abstract no. P1265]Vienna. Eur Heart J, 28
-
E. Antman, M. Hand, P. Armstrong, E. Bates, L. Green, L. Halasyamani, J. Hochman, H. Krumholz, G. Lamas, C. Mullany, D. Pearle, M. Sloan, Sidney Smith, D. Anbe, F. Kushner, J. Ornato, A. Jacobs, C. Adams, Jeffrey Anderson, C. Buller, M. Creager, S. Ettinger, J. Halperin, S. Hunt, B. Lytle, R. Md, R. Page, B. Riegel, L. Tarkington, C. Yancy (2008)
2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesCirculation, 117
-
R. Faaij, J. Burggraaf, R. Schoemaker, R. Amsterdam, Adam Cohen (2002)
Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin.British journal of clinical pharmacology, 54 3
-
J. Alexander, Kanwar Singh (2005)
Inhibition of Factor XaAmerican Journal of Cardiovascular Drugs, 5
-
J.-P. Bassand, C.W. Hamm, D. Ardissino (2007)
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of CardiologyEur Heart J, 28
-
Mohsin Farooq, Amer Qureshi, I. Squire (2007)
Early management of ST elevation myocardial infarction: a review of practiceExpert Opinion on Pharmacotherapy, 8
-
J. Herbert, M. Petitou, J. Lormeau, R. Cariou, J. Necciari, H. Magnani, P. Zandberg, R. Amsterdam, C. Boeckel, D. Meuleman (1997)
SR 90107A/Org 31540, a Novel Anti‐Factor Xa Antithrombotic AgentCardiovascular Drug Reviews, 15
-
D. Robinson, K. Wellington (2005)
Fondaparinux SodiumAmerican Journal of Cardiovascular Drugs, 5
-
K. Fox, J. Bassand, S. Mehta, L. Wallentin, P. Théroux, L. Piegas, V. Valentín, T. Moccetti, S. Chrolavicius, Rizwan Afzal, S. Yusuf (2007)
Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in NonST-Segment Elevation Acute Coronary SyndromesAnnals of Internal Medicine, 147
-
S. Mehta, P. Steg, C. Granger, J. Bassand, D. Faxon, J. Weitz, Rizwan Afzal, B. Rush, R. Peters, M. Natarajan, J. Velianou, D. Goodhart, M. Labinaz, J. Tanguay, K. Fox, S. Yusuf (2005)
Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention: Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation (ASPIRE) Pilot TrialCirculation, 111
-
G. Gerotziafas, I. Elalamy, F. Depasse, T. Chakroun, L. Bara, P. Arzoglou, M. Samama (2003)
On the mechanism of inhibition of tissue factor pathway by the synthetic pentasaccharide during coagulation of human plasmaBlood Coagulation & Fibrinolysis, 14
-
T. Mant, P. Fournié, C. Ollier, F. Donat, J. Necciari (2002)
Absence of Interaction of Fondaparinux Sodium with Digoxin in Healthy VolunteersClinical Pharmacokinetics, 41
-
Antonio Ortiz, A. Gitt, Yonathan Hasin, Kurt Huber, Ran Kornowski, J. Morais, J. Nordrehaug, S. Silber, P. Steg, Kristian Thygesen, M. Tubaro, A. Turpie (2007)
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromesEuropean Heart Journal, 28
-
F. Werf, D. Ardissino, A. Betriu, D. Cokkinos, E. Falk, K. Fox, D. Julian, M. Lengyel, F. Neumann, W. Rużyłło, Christian Thygesen, S. Underwood, A. Vahanian, F. Verheugt, W. Wijns (2003)
Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.European heart journal, 24 1
-
R.J. Peters, T. Rees Vellinga, J.P. Bassand (2007)
Efficacy and safety of fondaparinux in elderly patients with ST segment elevation myocardial infarction: data from the OASIS 6 trial [abstract no. 1025–138]J Am Coll Cardiol, 49
-
K.A. Bauer (2003)
New pentassaccharides for prophylaxis of deep vein thrombosisChest, 124
-
E.M. Antman, M. Hand, P.W. Armstrong (2008)
J Am Coll Cardiol -
S. Olson, R. Swanson, E. Raub-Segall, Tina Bedsted, M. Sadri, M. Petitou, J. Herault, J. Herbert, I. Björk (2004)
Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems Comparison with heparin and low-molecular-weight heparinThrombosis and Haemostasis, 92
-
D.M. Robinson, K. Wellington (2005)
Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolismAm J Cardiovasc Drugs, 5
-
H.L. Messmore, B. Griffin, J. Fareed (1989)
In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with plateletsAnn NY Acad Sci, 556
-
J. Walenga, W. Jeske, Lucienne Bara, M. Samama, J. Fareed (1997)
Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.Thrombosis research, 86 1
-
J. Herbert, J. Herault, A. Bernat, Van Amsterdam, J. Lormeau, M. Petitou, C. Boeckel, P. Hoffmann, D. Meuleman (1998)
Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.Blood, 91 11
-
J.M. Walenga, J. Fareed (1991)
Relative contribution of factor Xa and factor IIa: inhibition in the mediation of the antithrombotic actions of LMWHs and synthetic heparin pentasaccharidesThromb Haemorrh Disorders, 3
-
S. Yusuf, S.R. Mehta, S. Chrolavicius (2006)
N Engl J Med -
J. Bassand (2007)
Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm.European heart journal, 28 11
-
E. Antman, D. Anbe, P. Armstrong, Eric Bates, L. Green, M. Hand, J. Hochman, H. Krumholz, F. Kushner, G. Lamas, C. Mullany, J. Ornato, D. Pearle, M. Sloan, Sidney Smith (2004)
ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients WiThe Canadian journal of cardiology, 20 10
-
A. Bendetowicz, L. Bara, M. Samama (1990)
The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma.Thrombosis research, 58 5
-
M. Hamon, S. Mehta, G. Steg, D. Faxon, P. Kerkar, H. Rupprecht, J. Tanguay, Rizwan Afzal, S. Yusuf (2006)
Abstract 2654: Major Bleeding in Patients with Acute Coronary Syndrome Undergoing Early Invasive Management Can Be Reduced by Fondaparinux, Even in the Context of Trans-Radial Coronary Intervention: Insights from OASIS-5 TrialCirculation, 114
-
D. Carrie, C. Caranobe, S. Saivin, G. Houin, M. Petitou, J. Lormeau, C. Boeckel, D. Meuleman, B. Boneu (1994)
Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216Blood, 84
-
R. Peters, C. Joyner, J. Bassand, Rizwan Afzal, S. Chrolavicius, S. Mehta, A. Budaj, K. Fox, S. Yusuf, Oasis investigators (2006)
Abstract 3294: Fondaparinux versus Control (Placebo or Unfractionated Heparin) as an Adjunct to Thrombolytic Therapy in Acute Myocardial Infarction: an OASIS 6 SubstudyCirculation, 114
-
R.J. Peters, C. Joyner, J.P. Bassand (2006)
Fondaparinux versus control (placebo or unfractionated heparin) as an adjunct to thrombolytic therapy in acute myocardial infarction: an OASIS 6 Substudy [abstract no. 3071; plus poster]Circulation, 114
-
S. Mehta, C. Granger, J. Eikelboom, J. Bassand, L. Wallentin, D. Faxon, R. Peters, A. Budaj, Rizwan Afzal, S. Chrolavicius, K. Fox, S. Yusuf (2007)
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.Journal of the American College of Cardiology, 50 18
-
E. Antman (2008)
Is fondaparinux safer than enoxaparin for patients undergoing percutaneous coronary intervention?Nature Clinical Practice Cardiovascular Medicine, 5
-
M. Petitou, P. Duchaussoy, G. Jaurand, F. Gourvenec, I. Lederman, Jean-M. Strassel, T. Bârzu, B. Crépon, J. Herault, J. Lormeau, A. Bernat, J. Herbert (1997)
Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).Journal of medicinal chemistry, 40 11
-
J. Lormeau, J. Herault, Colette Gaich, T. Barzu, T. Dinther, A. Visser, J. Herbert (1997)
Determination of the anti-factor Xa activity of the synthetic pentasaccharide SR 90107A/ORG 31540 and of two structural analogues.Thrombosis research, 85 1
-
M. Simoons, I. Bobbink, J. Boland, M. Gardien, P. Klootwijk, A. Lensing, W. Rużyłło, V. Umans, A. Vahanian, F. Werf, U. Zeymer (2004)
A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.Journal of the American College of Cardiology, 43 12
-
G. Gerotziafas, L. Bara, M. Bloch, P. Makris, M. Samama (1998)
Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 9 7
-
N. Bijsterveld, A. Moons, S. Boekholdt, B. Aken, H. Fennema, R. Peters, J. Meijers, H. Büller, M. Levi (2002)
Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy VolunteersCirculation: Journal of the American Heart Association, 106
-
S. Yusuf, S. Mehta, S. Chrolavicius, Rizwan Afzal, J. Pogue, C. Granger, A. Budaj, R. Peters, J. Bassand, L. Wallentin, C. Joyner, K. Fox (2006)
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.The New England journal of medicine, 354 14
-
S. Yusuf, S. Mehta, S. Chrolavicius, Rizwan Afzal, J. Pogue, C. Granger, A. Budaj, R. Peters, J. Bassand, L. Wallentin, C. Joyner, K. Fox (2006)
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.JAMA, 295 13
-
M. Petitou, P. Duchaussoy, G. Jaurand (1997)
Synthesis and pharmacological properties of a close analogue of an antithrombotic pentassarcharideJ Med Chem, 40
-
H. Wienbergen, U. Zeymer (2007)
Management of acute coronary syndromes with fondaparinuxVascular Health and Risk Management, 3
-
E. Bates (2007)
New anticoagulant options for ST-elevation myocardial infarction and unstable angina pectoris/non-ST-elevation myocardial infarctionCurrent Cardiology Reports, 9
-
J.C. Lormeau, J.P. Herault, J.M. Herbert (1996)
Thromb Haemostat -
H. Messmore, B. Griffin, J. Fareed, E. Coyne, J. Seghatchian (1989)
In Vitro Studies of the Interaction of Heparin, Low Molecular Weight Heparin and Heparinoids with PlateletsAnnals of the New York Academy of Sciences, 556
-
B. Boneu, J. Necciari, R. Cariou, P. Sié, Gabaig Am, G. Kieffer, Dickinson Jp, G. Lamond, H. Moelker, T. Mant (1995)
Pharmacokinetics and Tolerance of the Natural Pentasaccharide (SR90107/ORG31540) with High Affinity to Antithrombin III in ManThrombosis and Haemostasis, 74
-
CB Granger, L Wallentin, A Avezum (2006)
Fondaparinux results in less bleeding than enoxaparin, irrespective of heparin use, for patients with acute coronary syndromes [abstract no. 2376]Eur Heart J, 27
-
W. Peacock, J. Hollander, R. Smalling, M. Bresler (2007)
Reperfusion strategies in the emergency treatment of ST-segment elevation myocardial infarction.The American journal of emergency medicine, 25 3
-
F. Donat, J. Duret, A. Santoni, R. Cariou, J. Necciari, H. Magnani, R. Greef (2002)
The Pharmacokinetics of Fondaparinux Sodium in Healthy VolunteersClinical Pharmacokinetics, 41
-
E. Braunwald, E. Antman, J. Beasley, R. Califf, M. Cheitlin, J. Hochman, Robert Jones, D. Kereiakes, J. Kupersmith, T. Levin, C. Pepine, J. Schaeffer, E. Smith, D. Steward, P. Théroux, R. Gibbons, J. Alpert, K. Eagle, D. Faxon, V. Fuster, T. Gardner, G. Gregoratos, R. Russell, Sidney Smith (2000)
ACC/AHA guidelines for the management of patients with unstable angina and non‐ST segment elevation myocardial infarction: Executive summary and recommendationsCatheterization and Cardiovascular Interventions, 51
-
Vijay Ramanath, K. Eagle (2007)
Evidence-Based Medical Therapy of Patients with Acute Coronary SyndromesAmerican Journal of Cardiovascular Drugs, 7
-
S.R. Mehta, P.G. Steg, C.B. Granger (2005)
Circulation -
K. Bauer (2003)
New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology.Chest, 124 6 Suppl
-
C. Ollier, R. Faaij, A. Santoni, T. Duvauchelle, P. Haard, R. Schoemaker, A. Cohen, R. Greef, J. Burggraaf (2002)
Absence of Interaction of Fondaparinux Sodium with Aspirin and Piroxicam in Healthy Male VolunteersClinical Pharmacokinetics, 41
-
S.T. Olson, I. Bjork, R. Sheffert (1992)
J Biol Chem -
N.A. Reynolds, C.M. Perry, L.J. Scott (2004)
Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgeryDrugs, 64
-
Jean Pieters, T. Lindhout, George Willems (1990)
Heparin-stimulated inhibition of factor IXa generation and factor IXa neutralization in plasma.Blood, 76 3
- Publisher
- Springer Journals
- Copyright
- Copyright © 2008 by Adis Data Information BV
- Subject
- Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
- ISSN
- 1175-3277
- eISSN
- 1179-187X
- DOI
- 10.1007/BF03256588
- pmid
- 18422394
- Publisher site
- See Article on Publisher Site
Abstract
indicated in Europe for preventing thrombus formation in patients with acute coronary syndromes (ACS; the focus of this review), including those with ST-segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), or unstable angina. The large (n = 20 078), well designed OASIS-5 trial showed that subcutaneous fondaparinux 2.5 mg/day for ≤8 days was noninferior to subcutaneous enoxaparin 1 mg/kg twice daily (once daily in those with renal dysfunction) in reducing death or ischemic events at 9 days and the efficacy was maintained for up to 6 months (study end) in patients with unstable angina or NSTEMI. During this time, major bleeding occurred in fewer fondaparinux than enoxaparin recipients, resulting in a benefit : risk balance favoring fondaparinux. The incidence of death or reinfarction at 30 days was significantly lower in recipients of subcutaneous fondaparinux 2.5 mg/day than in those who received usual care (including unfractionated heparin [UFH] treatment as indicated) in patients with STEMI in the large (n > 12 000) OASIS-6 trial. There were no differences in the incidence of major bleeding between these groups, resulting in a benefit : risk balance favoring fondaparinux. The specificity and selectivity of fondaparinux, combined with its long half-life and 100% bioavailability, allows
Journal
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 20, 2012